Halozyme develops and licenses drug-delivery technology that enables large-volume biologics to be given as subcutaneous injections instead of intravenous infusions. Its ENHANZE platform is based on a recombinant human hyaluronidase enzyme and is used in partnered products across oncology and other specialty areas. Revenue is driven largely by royalties, milestones and supply agreements with major pharmaceutical companies rather than a broad proprietary drug portfolio.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 264.9 | — | 118.1 | 17.7% |
| Q2 2025 | 325.7 | — | 165.2 | 41.6% |
| Q3 2025 | 354.3 | — | 175.2 | 8.9% |
| Q4 2025 | 451.8 | — | -141.6 | -188.3% |
| Q1 2026 | 376.7 | 42.2% | 150.1 | 27.1% |
| Q2 2026 | 481 | 47.7% | 229.9 | 39.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Neurocrine Biosciences, Inc. (NBIX), Regency Centers Corporation (REG), Jazz Pharmaceuticals plc (JAZZ), Ares Capital Corporation (ARCC), ICON Public Limited Company (ICLR), CoStar Group, Inc. (CSGP)